To the Editor: Alpha-2 macroglobulin (␣ 2 M) is a serum glycoprotein and a panproteinase inhibitor found in various tissues, including plasma and cerebrospinal fluid. ␣ 2 M is thought to inactivate proteinases by a specific trapping mechanism in the so-called "bait" region of the protein (1). ␣ 2 M is also a ligand for the LDL receptorrelated protein, and both are upregulated after brain injury and in regions of the brain affected by Alzheimer disease. Additionally, ␣ 2 M binds to the amyloid ␤ peptide (2, 3) , which leads to attenuation of both fibrillogenesis and neurotoxicity (4) and which is cleared by the LDL receptor-related protein. Recently, a pentanucleotide deletion in the 5Ј splice site of exon 18, which encodes a portion of the ␣ 2 M bait region, has been suggested to be genetically associated with an increased risk for developing Alzheimer disease (5) . ␣ 2 M and the ⑀4 allele of the apolipoprotein E gene seem to confer a similar degree of risk for developing late-onset Alzheimer disease. The conventional methods for measuring ␣ 2 M are ELISA, immunoblotting, or enzymatic assays, but these methods can not be applied to the detection of ␣ 2 M pentanucleotide polymorphism. The DNA-based method for detecting this polymorphism deletion is not amenable to large-scale screening (5, 6) .
The method described below is based on the observation that the ␣ 2 M pentanucleotide deletion polymorphism (6) leads to the loss of the HphI restriction site at the intronic sequence in the 5Ј splice site of exon 18 (Fig. 1A) . The primers amplify a 196-bp region in individuals without the pentanucleotide deletion ( Fig.  1B) . Genomic DNA was extracted from leukocytes, using HQIAamp (Qiagen), and was amplified by PCR using oligonucleotide primers ␣ 2 MF (5Ј-GGT GGC AAC TAT TAC ATT CTC TCA-3Ј) and ␣ 2 MR (5-ACT TAC TTT ACC ACC ACC AAA TCC-3Ј). In addition to the buffer and nucleotide components, each amplification reaction contained ϳ200 ng of genomic DNA, 20 pmol of each primer, and 2 U of Taq polymerase (Life Technologies) in a final volume of 50 L. The reaction mixture was first denatured at 94°C for 2 min and then subjected to 35 cycles of PCR (94°C for 1 min, 59°C for 40 s, 72°C for 40 s), after which it was incubated at 72°C for 10 min. A 20-L aliquot of the amplification product was then digested in the presence of 2.2 L of 10ϫ buffer and 20 U of HphI for at least 2 h at 37°C. Restriction digest products were size fractionated by electrophoresis on a 2% agarose gel with 1 mg/L ethidium bromide for 20 min at 200 V and detected directly under ultraviolet light. (Incomplete digestion may sometimes occur, which can be avoided by a purification step of the PCR product before enzymatic digestion. However, this does not interfere with the scoring of the alleles.) The PCR-amplified digestion products are shown in Fig.  1B along with representative ␣ 2 M genotypes. In a preliminary study of 367 individuals genotyped by this method, the allele frequency of one or two ␣ 2 M alleles was 19.1% in pa-tients with sporadic late-onset Alzheimer disease compared with 13.8% in age-matched unaffected individuals. We have encountered no difficulties in the samples tested, and we found this method to be well-suited to highthroughput routine clinical screening.
